{"analyses":[{"estimateComment":"A normal score \\<0 indicates fewer than expected events for the panitumumab plus FOLFOX arm and therefore a longer overall survival time.","groupDescription":"Overall survival comparisons in the wild-type KRAS Efficacy Analysis Set was performed at a significance level of 4.99% conditional on a statistically significant difference for PFS in the Wild-type KRAS Efficacy Analysis Set.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0723","pValueComment":"cP-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).","paramType":"Normal score","paramValue":"-1.80","statisticalMethod":"Stratified log-rank test"},{"estimateComment":"A normal score \\<0 indicates fewer than expected events for the panitumumab plus FOLFOX arm and therefore a longer overall survival time.","groupDescription":"Overall survival comparisons in the mutant KRAS Efficacy Analysis Set was performed at an significance level of 4.99% conditional on a statistically significant difference for PFS in the Mutant KRAS Efficacy Analysis Set.","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0678","pValueComment":"P-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).","paramType":"Normal score","paramValue":"1.83","statisticalMethod":"Stratified log-rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.3","upperLimit":"28.3","value":"23.9"},{"groupId":"OG001","lowerLimit":"17.6","upperLimit":"22.6","value":"19.7"},{"groupId":"OG002","lowerLimit":"13.1","upperLimit":"17.6","value":"15.5"},{"groupId":"OG003","lowerLimit":"16.5","upperLimit":"21.8","value":"19.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"325"},{"groupId":"OG001","value":"331"},{"groupId":"OG002","value":"221"},{"groupId":"OG003","value":"219"}],"units":"Participants"}],"description":"The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Wild-type KRAS - FOLFOX + Panitumumab"},{"description":"Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.","id":"OG001","title":"Wild-type KRAS - FOLFOX"},{"description":"Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.","id":"OG002","title":"Mutant KRAS - FOLFOX + Panitumumab"},{"description":"Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.","id":"OG003","title":"Mutant KRAS - FOLFOX"}],"paramType":"MEDIAN","populationDescription":"KRAS Efficacy Analysis Set","reportingStatus":"POSTED","timeFrame":"From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}